Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
Investor's Business Daily on MSN3d
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.
Viking Therapeutics has seen a significant drop, despite positive news and promising GLP-1 drug developments. Find out why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback